Understand the source comparison
Pinealon FDA Approved Status: International vs U.S. Regulatory Frameworks
FDA (United States) Not approved Research use only. No therapeutic claims Phase I–III U.S. trials + NDA submission No active IND application as of 2026 Russian Ministry of Health Approved (Pineamin) Clinical prescription for cognitive support Russian clinical
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- FDA (United States)
- Not approved
- Research use only. No therapeutic claims
- Phase I–III U.S. trials + NDA submission
- No active IND application as of 2026
- Russian Ministry of Health
- Approved (Pineamin)
- Clinical prescription for cognitive support
- Russian clinical trials (2003–2015)
- Approved under geroprotective drug classification
- EMA (European Union)
- Research use only
- EMA clinical trial pathway required
- Russian trial data does not transfer to EMA approval
- Health Canada
- Canadian clinical trial framework required
- No ANDS or NDS application filed
- TGA (Australia)
- TGA clinical trial pathway required
- Listed as research biochemical, not therapeutic good
- Bottom Line
- Pinealon is a foreign-approved pharmaceutical in Russia with no corresponding FDA approval. Researchers must treat it as a research-grade compound in the U.S.
- The table underscores a critical compliance point: FDA approval is jurisdiction-specific. Researchers citing Russian clinical trials as evidence of safety are referencing valid science. But not valid U.S. regulatory status. The FDA's position is explicit in its guidance documents on unapproved drugs: foreign approval does not constitute domestic approval, and marketing or distributing a compound for therapeutic use without FDA approval violates the Federal Food, Drug, and Cosmetic Act. Pinealon suppliers operating in the U.S. navigate this by restricting sales to verified research institutions and requiring documentation that the peptide will be used in laboratory protocols, not clinical administration.